S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
S&P 500   4,667.98 (+1.60%)
DOW   35,236.56 (+0.97%)
QQQ   400.03 (+2.26%)
AAPL   160.59 (+2.41%)
MSFT   337.95 (+2.51%)
FB   338.81 (+1.71%)
GOOGL   2,913.94 (+2.47%)
AMZN   3,588.40 (+2.39%)
TSLA   1,140.49 (+5.41%)
NVDA   329.61 (+4.63%)
BABA   131.95 (-1.05%)
NIO   40.28 (+0.73%)
CGC   11.13 (-4.79%)
AMD   159.99 (+3.35%)
GE   98.89 (+1.07%)
MU   85.18 (+2.11%)
T   24.02 (-0.83%)
F   19.86 (+0.56%)
DIS   147.61 (-0.34%)
ACB   6.50 (-4.27%)
AMC   37.16 (-1.25%)
PFE   53.84 (-0.30%)
BA   198.88 (-0.17%)
NASDAQ:MNKD

MannKind Stock Forecast, Price & News

$4.79
+0.16 (+3.46%)
(As of 11/29/2021 01:01 PM ET)
Add
Compare
Today's Range
$4.64
$4.82
50-Day Range
$4.15
$5.37
52-Week Range
$2.68
$6.25
Volume
42,149 shs
Average Volume
3.90 million shs
Market Capitalization
$1.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.82
30 days | 90 days | 365 days | Advanced Chart
Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter.


MannKind logo

About MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MNKD
CUSIP
56400P20
Employees
241
Year Founded
1991

Sales & Book Value

Annual Sales
$65.14 million
Book Value
($0.74) per share

Profitability

Net Income
$-57.24 million
Pretax Margin
-97.43%

Debt

Price-To-Earnings

Miscellaneous

Free Float
246,733,000
Market Cap
$1.20 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

1.65 out of 5 stars

Medical Sector

980th out of 1,392 stocks

Pharmaceutical Preparations Industry

464th out of 670 stocks

Analyst Opinion: 3.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












MannKind (NASDAQ:MNKD) Frequently Asked Questions

Is MannKind a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind
or view top-rated stocks.

How has MannKind's stock price been impacted by Coronavirus?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MNKD shares have increased by 334.5% and is now trading at $4.78.
View which stocks have been most impacted by COVID-19
.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for MannKind
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.07) by $0.03. During the same period last year, the company earned ($0.05) EPS.
View MannKind's earnings history
.

What price target have analysts set for MNKD?

6 Wall Street analysts have issued 12 month target prices for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate MannKind's stock price to reach $6.30 in the next year. This suggests a possible upside of 31.8% from the stock's current price.
View analysts' price targets for MannKind
or view top-rated stocks among Wall Street analysts.

Who are MannKind's key executives?

MannKind's management team includes the following people:

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.68%), Geode Capital Management LLC (1.71%), Emerald Advisers LLC (1.69%), Emerald Mutual Fund Advisers Trust (1.39%), Goldman Sachs Group Inc. (0.57%) and Morgan Stanley (0.53%). Company insiders that own MannKind stock include Alejandro Galindo, David Thomson, Michael Castagna, Steven B Binder, Stuart A Tross and Stuart A Tross.
View institutional ownership trends for MannKind
.

Which major investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Citigroup Inc., Goldman Sachs Group Inc., Parkman Healthcare Partners LLC, Morgan Stanley, BlackRock Inc., and GSA Capital Partners LLP.
View insider buying and selling activity for MannKind
or view top insider-selling stocks.

Which major investors are buying MannKind stock?

MNKD stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Pura Vida Investments LLC, Emerald Mutual Fund Advisers Trust, UBS Group AG, Monarch Partners Asset Management LLC, Jump Financial LLC, Marshall Wace LLP, and SG Americas Securities LLC. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind
or or view top insider-buying stocks.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.78.

How much money does MannKind make?

MannKind has a market capitalization of $1.20 billion and generates $65.14 million in revenue each year. The biopharmaceutical company earns $-57.24 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 241 workers across the globe.

When was MannKind founded?

MannKind was founded in 1991.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

Where are MannKind's headquarters?

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at (818) 661-5000, via email at [email protected], or via fax at 661-775-2081.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.